7432-S in complicated urinary tract infections

Mikio Kishi, Daisuke Yamada, Yoshitsugu Nasu, Masaya Tsugawa, Hiromi Kumon, Hiroyuki Ohmori, Katsuyoshi Kondo, Atsushi Kondo, Katsuichi Nanba, Teruaki Akaeda

Research output: Contribution to journalArticlepeer-review


We evaluated 7432-S, a new oral cephem, basically and clinically. 1) The antibacterial activity of 7432-S against 180 strains isolated from urinary tract infections were compared with those of cefaclor, cefadroxil, cephalexin and ampicillin. Its activity against Staphylococcus epidermidis and Enterococcus faecalis was weak, and inferior or equal to the reference drugs; but its activity against Escherichia coli, Klebsielkt pneumoniae, Proteus mirabilis, Proteus vulgaris and Morganella morganii was far superior. Although approximately half the strains of Citrobacter sp., Enterobacter cloacae, Enterobacter aerogenes proved resistant, 7432-S nevertheless showed stronger activity than the reference drugs. The MICs of 7432-S against 15 of 19 strains of Serratia marcescens were less than 12.5μg/ml. Its activity against Pseudomonas aeruginosa was weak, but superior to the other drugs. 2) Twenty-five patients with complicated urinary tract infections were treated with daily doses of 200 mg or 300 mg of 7432-S. The overall clinical efficacy rate was 68%. A side-effect, mild diarrhea, was noted in only one case, and no abnormal laboratory findings were observed.

Original languageEnglish
Pages (from-to)478-488
Number of pages11
Publication statusPublished - Jan 1 1989

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology


Dive into the research topics of '7432-S in complicated urinary tract infections'. Together they form a unique fingerprint.

Cite this